$77.36
1.1%
Price vs. AI Score (Last 150 days)
Data gathered: December 1
Data gathered: December 1
Data Bits
| Data Bits | Value / Change | Benchmark |
|---|---|---|
| Job Posts | 337 -3.2% |
|
| Sentiment | 96 0% |
|
| Webpage traffic | 577,000 3.2% |
|
| Employee Rating | 78 0% |
|
| Google Adspend | $40,739 N/A |
|
| Google Trends | 12 -78.6% |
|
| Linkedin Employees | 14,391 N/A |
|
| Lobbying Cost | $797,000 0% |
|
| NPS | 19 -9.5% | N/A |
| Patents | 489 0.2% |
|
| 4chan Mentions | 0% |
|
| Facebook Engagement | 35 2.9% |
|
| Facebook followers | 23,055 0% |
|
| Stocktwits Mentions | 12 20% |
|
| Stocktwits Subscribers | 76,064 0% |
|
| Twitter Followers | 73,883 0% |
|
| Youtube Subscribers | 5,120 0% |
|
| Instagram Followers | N/A | N/A |
| News Mentions | -100% |
|
| Reddit Mentions | 1 0% |
|
| ESG | 82 0% |
|
| Business outlook | 70 0% |
|
In the news
 |
17 Ideal Pre-Crash Recovery December Divi-DogsNovember 30 - SeekingAlpha |
2 Biotech Stocks You Can Buy and Hold for the Next DecadeNovember 29 - Yahoo |
|
 |
Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023November 29 - Yahoo |
Piper Sandler Reaffirms Their Buy Rating on Gilead Sciences (GILD)November 29 - TipRanks |
|
Gilead management to meet with OppenheimerNovember 29 - Thefly.com |
|
 |
Smart or AI In-Vitro Diagnostics Market to Record an Exponential CAGR by 2031 - Exclusive Report by InsightAce AnalyticNovember 29 - PR Newswire UK |
About Gilead Sciences
Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.
| Price | $77.36 |
| Target Price | Sign up |
| Market Cap | $93.7B |
| Dividend Yield | 0.0399 |
| Industry | Biotechnology |
Similar companies
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | |
|---|---|---|---|---|---|
| Q3 '23 | 6.82B | 3.48B | 3.34B | 2.18B | 3.16B |
| Q2 '23 | 6.42B | 3.89B | 2.53B | 1.05B | 2.42B |
| Q1 '23 | 6.12B | 3.27B | 2.85B | 1.01B | 2.1B |
| Q4 '22 | 7.16B | 4.09B | 3.07B | 1.64B | 2.76B |
| Q3 '22 | 6.82B | 3.05B | 3.77B | 1.79B | 3.11B |
Insider Transactions
| Dickinson Andrew D filed to sell 104,003 shares at $80. October 18 '23 |
| Parsey Merdad filed to sell 70,130 shares at $77. September 13 '23 |
| Dickinson Andrew D filed to sell 107,587 shares at $80. July 21 '23 |
| Parsey Merdad filed to sell 29,402 shares at $76.9. June 14 '23 |
| Parsey Merdad filed to sell 70,130 shares at $79. March 14 '23 |
Read more about Gilead Sciences and their earnings, price prediction, job posts, sentiment, webpage traffic, employee rating, google adspend, google trends, linkedin employees, lobbying cost, nps, patents, 4chan mentions, facebook engagement, facebook followers, stocktwits mentions, stocktwits subscribers, twitter followers, youtube subscribers, instagram followers, news mentions, reddit mentions, esg, business outlook.